Bristol-Myers Squibb Co
NYSE:BMY
Bristol-Myers Squibb Co
NYSE:BMY
Price:
41.54 USD
-1.89%
Market Closed
Updated:
May 23, 2024
Bristol-Myers Squibb Co
Deferred Income Tax
|
Bristol-Myers Squibb Co
Deferred Income Tax Peer Comparison
Comparables:
JNJ
PFE
MRK
ZTS
LLY
Competitive Deferred Income Tax Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Deferred Income Tax | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Deferred Income Tax
$442m
|
CAGR 3-Years
-56%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
19%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Deferred Income Tax
$3.2B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-4%
|
|
|
Pfizer Inc
NYSE:PFE
|
Deferred Income Tax
$931m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-28%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Deferred Income Tax
$922m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-17%
|
|
|
Zoetis Inc
NYSE:ZTS
|
Deferred Income Tax
$136m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-8%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Deferred Income Tax
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Bristol-Myers Squibb Co's Deferred Income Tax?
Deferred Income Tax
442m
USD
442m
USD
Based on the financial report for Mar 31, 2024, Bristol-Myers Squibb Co's Deferred Income Tax amounts to 442m USD.
What is Bristol-Myers Squibb Co's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
19%
19%
Over the last year, the Deferred Income Tax growth was -72%. The average annual Deferred Income Tax growth rates for Bristol-Myers Squibb Co have been -56% over the past three years , and 19% over the past ten years .
You don't have any saved screeners yet
